Literature DB >> 27047954

Combination therapy with TLR7 agonist and radiation is effective for the treatment of solid cancer.

Hiroyasu Ito1.   

Abstract

Entities:  

Year:  2016        PMID： 27047954      PMCID： PMC4791338          DOI： 10.21037/atm.2015.12.49

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

Review 1.  Innate immune sensing of cancer: clues from an identified role for type I IFNs.

Authors:  Thomas F Gajewski; Mercedes B Fuertes; Seng-Ryong Woo
Journal:  Cancer Immunol Immunother       Date:  2012-06-22       Impact factor: 6.968

2.  Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation.

Authors:  Mong-Hsun Tsai; John A Cook; Gadisetti V R Chandramouli; William DeGraff; Hailing Yan; Shuping Zhao; C Norman Coleman; James B Mitchell; Eric Y Chuang
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

Review 3.  Immune checkpoint modulation: rational design of combination strategies.

Authors:  Dmitriy Zamarin; Michael A Postow
Journal:  Pharmacol Ther       Date:  2015-01-10       Impact factor: 12.310

Review 4.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 5.  Toll-like receptor agonists in cancer therapy.

Authors:  Sylvia Adams
Journal:  Immunotherapy       Date:  2009-11       Impact factor: 4.196

6.  NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

Authors:  Y Kawarada; R Ganss; N Garbi; T Sacher; B Arnold; G J Hämmerling
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

7.  Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.

Authors:  Sebastian Schölch; Conrad Rauber; Alexandra Tietz; Nuh N Rahbari; Ulrich Bork; Thomas Schmidt; Christoph Kahlert; Uwe Haberkorn; Mark A Tomai; Kenneth E Lipson; Rafael Carretero; Jürgen Weitz; Moritz Koch; Peter E Huber
Journal:  Oncotarget       Date:  2015-03-10

8.  A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.

Authors:  Amy L Adlard; Simon J Dovedi; Brian A Telfer; Erina Koga-Yamakawa; Charlotte Pollard; Jamie Honeychurch; Timothy M Illidge; Masashi Murata; David T Robinson; Philip J Jewsbury; Robert W Wilkinson; Ian J Stratford
Journal:  Int J Cancer       Date:  2014-01-17       Impact factor: 7.396

9.  Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

Authors:  Simon J Dovedi; Monique H M Melis; Robert W Wilkinson; Amy L Adlard; Ian J Stratford; Jamie Honeychurch; Timothy M Illidge
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

Review 10.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110
View more
  2 in total

1.  ICAM-1 orchestrates the abscopal effect of tumor radiotherapy.

Authors:  Yang Zhao; Ting Zhang; Yanpu Wang; Dehua Lu; Jinhong Du; Xun Feng; Haoyi Zhou; Ning Liu; Hua Zhu; Shangbin Qin; Chenxin Liu; Xianshu Gao; Zhi Yang; Zhaofei Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

2.  Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.

Authors:  Hua Zhang; Wei-Lun Tang; Azadeh Kheirolomoom; Brett Z Fite; Bo Wu; Kenneth Lau; Mo Baikoghli; Marina Nura Raie; Spencer K Tumbale; Josquin Foiret; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; R Holland Cheng; Alexander D Borowsky; Katherine W Ferrara
Journal:  J Control Release       Date:  2020-11-13       Impact factor: 9.776
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.